EUCTR2009-010173-20-FR进行中（未招募）1 期
A MULTICENTER, OPEN LABEL STUDY TO INVESTIGATE THE FEASIBILITY AND EFFICACY OF A SMOKING CESSATION PROGRAM WITH VARENICLINE IN PATIENTS UNDERGOING ELECTIVE SURGERY
Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK0 个研究点目标入组 100 人开始时间: 2009年8月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Have evidence of a personally signed and dated informed consent document indicating that the subject (or legally acceptable representative) has understanding of all aspects of the study.
- •2. Male or female cigarette or cigarillo smokers aged 18 or over who are motivated to stop smoking before surgery.
- •3. Subjects must have smoked an average of at least 10 cigarettes or cigarillos per day during the past year, with no period of abstinence greater than 3 months in the past year. (Subjects who only smoke cigars and/or pipes are not eligible.)
- •4. Subjects must have smoked an average of at least 10 cigarettes or cigarillos per day over the month prior to the screening visit.
- •5. Subjects must be due to undergo planned elective surgery: orthopaedic (eg, elective hip or knee joint replacement) or plastic surgery (eg, abdominoplasty) or general surgery (eg, cholecystecomy, partial thyroidectomy, hernia repair) or vascular surgery (eg, carotid endarterectomy). Surgery should be scheduled to start at 8 weeks +/-10 days after the start of study drug treatment.
- •6. Subjects where the elective surgery is expected to produce a scar at least 3 cms long (or if there is more than one scar, the combined length of the scars is expected to be at least 3 cms long).
- •7. Subjects willing to return to hospital between 1-3 days post-surgery and between 6-10 days post-surgery for assessment of wound healing (or the expected period of hospitalisation covers these time periods).
- •8. If female, be not of childbearing potential (ie, surgically sterile or postmenopausal for at least two years), or be non-pregnant and using an acceptable method of birth control (such as implants, injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomised partner) for a least one month prior to the screening visit if necessary, and for the duration of the study period. Subject must also agree not to breastfeed for the duration of the study period.
- •9. Subjects must be likely to comply with the protocol, scheduled visits, laboratory tests and medication regimen.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects for whom the planned surgical procedure is anticipated to cause marked suppression of gastro-intestinal activity lasting greater than 24 hours.
- •2. Subjects who have an uncontrolled, unstable clinically significant medical condition (eg, renal, hepatic, endocrine, respiratory, cardiovascular, haematologic, immunologic, cerebrovascular disease, or malignancy), which, in the opinion of the investigator, may render them unsuitable for the study and/or interfere with the interpretation of safety or efficacy evaluations. Diabetic subjects may be included in the study if their condition is stable and they satisfy anaesthetic criteria. Patients with renal impairment may be included in the study if the impairment is not severe.
- •3. Subjects currently suffering with depression, or who have been diagnosed with depression or treated with an anti-depressant for their depression within the past 12 months. Subjects should be excluded if their score at the screening or baseline administration of the Patient Health Questionnaire (PHQ-9) is =5, or if they have a score of >0 on item 9 regarding suicidal ideation or behaviour.
- •4. Subjects with any history of suicidal ideation or suicidal behaviour as assessedby the Columbia Suicide-Severity Rating Scale (C-SSRS; Baseline Version) in the past 12 months, or at the time of the Baseline Visit.
- •5. Subjects with a past or present history of psychosis; subjects who have experienced anxiety disorders (including anxiety attacks) and bipolar disorder over the past 12 months or who are receiving treatment for these disorders.
- •6. Subjects with newly diagnosed or uncontrolled hypertension (eg, systolic blood pressure > 150 mmHg or diastolic blood pressure > 95 mmHg at screening/baseline) requiring new treatment or changes in treatment to bring blood pressure under control.
- •7. Subjects with evidence or history of serious or life-threatening allergic reactions to drugs (for example anaphylaxis or Stevens-Johnson syndrome).
- •8. Subjects with a history of drug (except nicotine) or alcohol abuse or dependence within the past 12 months.
- •9. Subjects receiving concomitant treatment with another investigational drug within 30 days of the study baseline visit or with plans to take another investigational drug within 30 days of study completion.
- •10. Subjects who are receiving or have received any other pharmacotherapy for smoking cessation (eg, bupropion or nicotine replacement therapy) or have started significant nondrug therapy (eg, hypnotherapy or acupuncture) for smoking cessation within the last 4 weeks.
- •11. Subjects who do not agree to completely abstain from using noncigarette/ cigarillo tobacco products (including, for example, pipe tobacco, cigars, snuff, nicotine replacement therapy, etc.) during study participation.
- •12. Subjects who donate blood or blood components while receiving study drug or within 1 month of the completion of the study treatment.13. Subjects unable and/or unlikely to comprehend and follow the study protocol, including subjects unable and/or unwilling to participate in the non-treatment follow up.
- •14. Subjects who in the investigator’s opinion will be unlikely to commit to the study.
- •15. Subjects with any other contraindication listed in the SmPC including hypersensitivity to Varenicline or to any of the excipients.
研究者
相似试验
进行中（未招募）
不适用
A MULTICENTER, OPEN LABEL STUDY TO INVESTIGATE THE FEASIBILITY AND EFFICACY OF A SMOKING CESSATION PROGRAM WITH VARENICLINE IN PATIENTS UNDERGOING ELECTIVE SURGERY - NDSmoking cessation in patients scheduled for elective surgery.MedDRA version: 12.0Level: LLTClassification code 10053325Term: Smoking cessation therapyEUCTR2009-010173-20-ITPfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK100
进行中（未招募）
不适用
A trial to evaluate the saftey, tolerability, the absorption and distribution in the body of Lacosamide syrup as adjunctive therapy in children with patial onset seizures.Epilepsy, partial onset seizuresMedDRA version: 14.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-001558-27-Outside-EU/EEACB BIOSCIENCES, Inc42
进行中（未招募）
不适用
A trial to evaluate the saftey, tolerability, the absorption and distribution in the body of Lacosamide syrup as adjunctive therapy in children with patial onset seizures.Epilepsy, partial onset seizuresMedDRA version: 16.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-001558-27-BECB BIOSCIENCES, Inc42
进行中（未招募）
1 期
Study to investigate safety and tolerability of intravenous lacosamide as replacement of oral lacosamide in children.MedDRA version: 18.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEpilepsyEUCTR2014-003294-42-ITCB BIOSCIENCES Inc.75
进行中（未招募）
1 期
Study to investigate safety and tolerability of intravenous lacosamide in children.MedDRA version: 20.0 Level: PT Classification code 10015037 Term: Epilepsy System Organ Class: 10029205 - Nervous system disordersEpilepsyEUCTR2014-003294-42-DECB BIOSCIENCES Inc.75